Bladder cancer mortality in diabetics in relation to saccharin consumption and smoking habits. The frequency with which diabetes mellitus was mentioned on the death certificates of 18 733 patients dying from bladder cancer has been compared with that of 19 709 patients dying from other cancers (excluding cancer of the lung and pancreas). The estimated relative risk of bladder cancer in diabetics was 0 98 with 95 % confidence limits 0 70-1 *38. There was no increase in risk of bladder cancer in patients with diabetes of long duration. Diabetics were shown by questionnaire to consume substantially more saccharin than non-diabetics, and the duration of regular saccharin use by diabetics was highly correlated with the duration of diabetes. There was therefore no evidence from this study that consumption of above average amounts of saccharin had led to bladder cancer in diabetics. The proportion of current smokers among diabetics was significantly less than among non-diabetics, and this may account for a low relative risk of lung cancer in the former (0 *72). Animal studies have shown that saccharin consumption may influence the development of cancer of the bladder (Allen et al., 1957; Hicks, Wakefield, and Chowaniec, 1973; BIBRA Information Bulletin, 1973) . We therefore examined the trends in saccharin consumption and bladder cancer mortality in England and Wales (Armstrong and Doll, 1974) . There was a sharp rise in saccharin consumption with the beginning of the second world war; consumption fell somewhat with the end of sugar rationing in 1953 but has since risen to much higher levels. There was no apparent effect of this rise upon bladder cancer rates, but this did not exclude the possibility ofan association in individuals who had consumed large amounts of saccharin. We have, therefore, now studied retrospectively the occurrence of bladder cancer in patients with diabetes mellitus, a group of individuals who consume more than average amounts of saccharin (Beringer, 1973) . Kessler (1970) found no increase in bladder cancer mortality in a prospective study of diabetics (21 observed against 29 * 6 expected), but the period covered may have been too early to observe any effect of saccharin.
We have also documented the saccharin consumption habits of diabetics and obtained data on their use of cigarettes, as cigarette smoking is known to be associated with bladder cancer (Lockwood, 1961; Cole et al., 1971; Doll, 1972) .
METHOD BLADDER CANCER MORTALrrY
All death certificates assigned to bladder cancer as the underlying cause were scrutinized for any mention of diabetes mellitus in all persons dying in England and Wales between 1 January 1966 and 31 December 1972. Similar data on deaths assigned to other cancers as the underlying cause were obtained from the samples of death certificates coded for multiple causes by the Registrar-General for England and Wales from all deaths in the same period. The numbers and sources of bladder and other cancer deaths included in the study are shown in Table I . The sources given for the 'other cancers' were determined by the nature of the RegistrarGeneral's samples. These samples were selected randomly from deaths in the whole of England and This clinic has about 3 000 regular attenders and accepts referrals of patients of any degree of severity from general practitioners in Oxford and surrounding areas. Questionnaires were also mailed to 200 individually matched control patients who were selected randomly from non-diabetics of the same sex and within the same 5-year age group currently on the list of the same general practice as the diabetic. If no reply was received, a further questionnaire was mailed and, if necessary, the patient was visited by a research assistant. The questionnaire covered the present and past use of artificial sweeteners:
in tablet or liquid form added to food during meal preparation in already prepared low-calorie foods in conventional and low-calorie soft drinks. Questions were also asked regarding the history of diabetes mellitus, body height and weight, occupation, religious affiliation, and smoking habits.
SMOKING HABrrS
Data on the smoking habits of diabetics were obtained from the Boston Collaborative Drug Surveillance Program (Jick et al., 1973) 
REsULTS

BLADDER CANCER MORTALrrY
The observed and expected numbers of patients with both bladder cancer and diabetes mellitus on the death certificate are shown in Table II . The expected numbers of certificates with mention of diabetes were calculated from the pooled observations for bladder and other cancer deaths within each 10-year age group and each calendar year group (Table 1) . The other cancers included all other types of cancer except cancers of the pancreas and lung, which were excluded because their incidence rates in diabetics were thought to be different from the rates in the general population (Kessler, 1970) . These exclusions had very little effect on the expected (0*50-10*1)
Expected numbers calculated from the pooled experience of bladder (or lung) cancer and the remaining cancers in each 10-year age group
and each calendar year group (Table I ) tEstimated risk of bladder or lung cancer in diabetics relative to risk of unity in non-diabetics tObserved number different from expected number P < -02 (X2 = 6-0; Mantel and Haenszel, 1959) From data on the number of saccharin tablets and glasses of soft drinks currently consumed daily, an estimate was made of the daily saccharin consumption by each individual from these sources. Each tablet was assumed to contain 125 mg of saccharin, each glass of low-calorie soft drink 50 mg, and each glass of conventional soft drink 10 mg. The average and range of saccharin consumption for each group of patients are shown in Table V . Diabetics of either sex consumed significantly more saccharin than did non-diabetics, whereas diabetic men consumed more saccharin than did diabetic women (P<0 01) and non-diabetic women consumed more saccharin than did non-diabetic men (P<0 05).
Of the 14 men and 20 women with diabetes of more than 20 years' duration, 10 men (71 %; 95% confidence limits 40 to 93%) and 4 women (20%; 95% confidence limits 4 to 44%) had also used saccharin tablets daily for more than 20 years. The longest durations of use with the amounts used were: 4 tablets daily for 53 years in a male diabetic; 5 tablets daily for 44 years in a female diabetic; 4 tablets daily for 10 years in a male non-diabetic; and 10 tablets daily for 34 years in a female nondiabetic. Among diabetics currently using saccharin tablets daily, the duration of daily use was highly correlated with, and in most cases equal to, the duration of diabetes (correlation coefficient 0'95 for men and 0 93 for women). The data for men are plotted in the Figure. The daily use of saccharin tablets was examined within each group of patients according to their attitude to their body weight. Patients were classified as concerned about their weight ifthey considered themselves to be overweight or if tney were currently dieting or had previously dieted to lose weight. Attitude to weight did not appear to influence the use of saccharin tablets by diabetics or by male non-diabetics, whereas concern about body weight was strongly associated with their use in female non-diabetics (19 -3 % of those concerned about their weight used saccharin daily compared with 3 9 % of unconcerned; P<0 05).
Among diabetics, there was no association between the type of diabetic therapy or the strictness with which patients said they followed their diabetic diet and saccharin use. The percentage of patients using saccharin from any source did not change significantly with duration of diabetes and was not associated with age at onset of diabetes.
The distribution of current or pre-retirement occupations was similar in the diabetics and the non-diabetics. There were also no appreciable differences between the smoking habits of diabetics and non-diabetics, but the sample size in this study was insufficient to detect small differences so that data on smoking were sought from another source.
CIGARETrE SMOKING HABITS
The smoking habits of patients included in the Boston study are shown in Bladder cancer nmrtality in diabetics categories (Mantel and Haenszel, 1959) and used to assign the probability levels shown. There was a significant deficit of current smokers of one packet of cigarettes or less per day among both male and female diabetics. These deficits persisted when Jewish patients were excluded and were largely due to an excess of diabetic patients who had never smoked and, less markedly, to an excess of exsmokers. Examination of the age-distribution of these differences showed that they were predominantly in those aged over 60 years.
In view of this difference with age in the Boston data, the smoking habits of 707 patients (345 men and 362 women) attending the Radcliffe Infirmary diabetic clinic were recorded to see whether this was an effect of duration of diabetes. A further 26 patients (3 5% of the total approached) attended the clinic during the survey period but refused to be interviewed or were missed by the interviewers. Age-standardized percentages of patients in the various smoking categories are shown in Table VII , subdivided by duration of diabetes. Standardization was performed over 10-year age groups in this case by the indirect method using the overall percentages for each smoking category as the standards. This method was preferred to the direct method because of the very small numbers of patients in some of the age-duration groups. In men, there was a significantly lower proportion of current smokers and correspondingly higher proportion of ex-smokers among diabetics of 20 or more years' duration compared with those of less than 20 years' duration. No such differences were seen in women. Of the 134 male ex-smokers, 48 % had given up smoking before the Significance of difference from diabetics of < 20 years' duration:
tP<0.01
tSome of these percentages do not quite add up to 100 because of the use of the indirect method of standardization onset ofdiabetes and 8 % gave up in the same year as diabetes was diagnosed; the remainder gave up at varying periods up to more than 20 years after diagnosis. DISCUSSION The validity of this study for determining the relative risk of bladder cancer in diabetics is dependent upon the absence of a difference in the frequency with which diabetes mellitus is detected in patients with different types of cancer (or vice versa), or in the frequency with which diabetes mellitus is recorded on the death certificates of diabetics who die from bladder cancer compared with that in diabetics who die from other cancers. Biases may have been introduced by knowledge of the possible association between artificial sweeteners and bladder cancer, which was first publicized in 1969, and by the fact that patients with bladder cancer would be more likely to have had their urine examined and, perhaps, diabetes diagnosed (and vice versa) than would have patients with other cancers. Both these possible types of bias would, however, have led to an overestimation rather than to an underestimation of the risk of bladder cancer in diabetics.
Amore serious problem is the possibleconfounding effect of cigarette smoking on the relationship between bladder cancer and diabetes mellitus. The Boston data (Table VI) suggest that a lower proportion of diabetics smoke cigarettes than do nondiabetics, although the differences between the two groups are small. Using the proportions of current smokers among patients in Boston, it may be estimated that, if the relative risk of bladder cancer in current smokers compared with current nonsmokers is 2 0, only a 4% reduction in bladder cancer risk (relative risk of 0 * 96) would be expected in diabetics. Although the Boston data cannot necessarily be applied to the population of diabetics in England and Wales, it appears that the confounding effect of smoking habits in this study is unlikely to be large.
If the possible effects of the biases referred to above are ignored, the results of this study suggest that the relative risk of bladder cancer in diabetics is unlikely to be greater than 1-38 in both sexes together or 1 -60 if we limit our attention to diabetic men who consume substantially more saccharin than do diabetic women (Table II Because there is usually a long, latent period between initial exposure to a carcinogen and the subsequent development of cancer, it may be that too few diabetics had consumed saccharin for long enough to produce an effect on bladder cancer mortality in the group as a whole. There was no evidence, however, of an increased risk of bladder cancer in patients with diabetes of 20 or more years' duration. If the Oxford data can be applied to the whole of England and Wales, then at least 40% of the men with diabetes of this duration would have also consumed saccharin tablets daily for more than 20 years.
In this study we have investigated the relationship between saccharin consumption and bladder cancer indirectly, through their common association with diabetes mellitus. A recent investigation has examined the relationship directly by studying the consumption of artificial sweeteners in patients with bladder cancer and matched controls (Morgan and Jain, 1974) . These workers also found no positive association between artificial sweeteners and bladder cancer, and perhaps a negative association in women (estimated relative risk 0 35). Their results are difficult to interpret, however, as the response rates of both patients and controls were low (69% and 57 % respectively) and the control series was limited to men and women with single diseases which might have affected the use of saccharin (men with benign prostatic hypertrophy and women with stress incontinence).
A secondary result of our study is the confirmation of Kessler's (1970) finding of a lower risk of lung cancer among diabetics. It seems likely that this difference is due, at least in part, to the lower proportion of smokers among diabetics. Kessler suggested that the lower risk which he observed in diabetics in Boston may have been due to the high proportion of Jews. This would be unlikely to account for such a difference in England and Wales (none of the 197 Oxford diabetics studied was Jewish) and the smoking habit differences between diabetics and non-diabetics persisted when only non-Jews were examined (Table VI) . If we assume a relative risk of 10 for lung cancer in smokers compared with non-smokers, it may be estimated that the difference in smoking habits between diabetics and non-diabetics might account for a 12% reduction in lung cancer risk in diabetic men and an 11 % reduction in diabetic women. Although these estimates are smaller than the observed reductions (26% and 35%) in this study, they fall well within their 95 % confidence limits.
The lower prevalence of current smokers among diabetics in Boston may be of some interest. The excess of diabetic 'never' smokers suggests either that non-smokers are more prone to develop diabetes than are smokers, or that the selective advantages in favour of survival of non-smoking diabetics are greater than for the survival of non-smokers in general. Paffenbarger and Wing (1973) did not find that cigarette smoking protected against the development of maturity-onset diabetes, whereas data from the Framingham study (Kannel and Gordon, 1973) suggest a synergistic effect of cigarette smoking and glucose intolerance in the production of ischaemic heart disease. Such an effect would give non-smoking diabetics a selective advantage for survival over smoking diabetics which would be in excess of that experienced by non-smokers over smokers in the general population. In our data, however, the proportion of 'never' smokers among diabetics did not increase with duration of diabetes (Table VII) . The proportion of ex-smokers did increase with duration of diabetes, but this could be explained equally well as an effect of pressure from attending physicians to stop smoking as by selective mortality from continuing smoking.
In this study we have been unable to find evidence of an increased risk of bladder cancer in diabetics, some of whom must have consumed above average amounts of saccharin for more than 20 years. We should, of course, not have found an excess risk of bladder cancer if saccharin were equally carcinogenic for other organs as for the bladder because the control patients were patients with other cancers. This, however, seems rather unlikely. Certainly, the animal data do not suggest that saccharin has a general carcinogenic effect in all sites. Our data cannot exclude the possibility of a weak carcinogenic effect of saccharin upon the human bladder, but no data can be expected to do this unless the agent actually protects against the development of cancer, as it is impossible to prove a negative. So far as they go, the data are reassuring and encourage the belief that saccharin is not carcinogenic to man in the amounts commonly used by diabetics.
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